One Honest Question Is a Whole Discipline, a Lesson from the 2026 Lasker Awards
Yanagisawa says he never thought he would end up in sleep. He was studying a group of receptors that nobody yet knew were triggered by anything. Thirty years later, he shares this year's [Lasker Award](/appendix#lasker-award), and a whole new class of drugs has come out of that lab. This is not a story about "staying passionate." It is a story about the fact that the question you ask twenty years before its answer does not tell you what its answer will be for.
A reflection on Nicoletta Lanese's "'America's Nobel' prizes go to sleep and hemophilia researchers, and to Michael J. Fox for Parkinson's advocacy" (Live Science, 2026). Read the original →
The 2026 Lasker Awards were announced on September 9. Three categories, three completely different research paths. Set them side by side and something less like "science news" comes into view. It reads more like three stories about time.
The first category, the Basic Medical Research Award, went to Masashi Yanagisawa of the University of Tsukuba and Emmanuel Mignot of Stanford. Working independently, they discovered a small neuropeptide called orexin. It is made by a specific group of cells in the hypothalamus, and its job is to keep us awake. When the cells that make it disappear, a person cannot stay awake, and that is at the heart of narcolepsy.
The sentence in the coverage worth hearing clearly is Yanagisawa's own. He says he never thought he would end up in sleep. His lab was chasing a group of "orphan" receptors, receptors already known to exist but with no known trigger. He calls what they were doing a "biochemical fishing expedition." Their fifth or sixth receptor happened to hit, they landed on the small peptides that fit, and tracing those peptides back, they arrived at the hypothalamus and at the mechanism of wakefulness itself.
Mignot came at the same territory from the opposite direction. He had been following a line of dogs that suddenly collapsed, trying to work out what was missing in them. What was missing was orexin. Two long runs, colliding in mid-course. The reason this work rises to the top prize is not that there was one lightning-strike moment. It is that two people, on very different questions, walked honestly for many years, and met in the middle. Their work also opened up a whole new class of insomnia drugs and, more recently, a whole new class of narcolepsy drugs.
The second category, the Clinical Medical Research Award, went to three scientists at the Japanese pharmaceutical company Chugai: Kunihiro Hattori, Takehisa Kitazawa, and Tomoyuki Igawa. Together they built a bispecific antibody called emicizumab, used to treat hemophilia A. In this disease, a genetic mutation prevents the body from producing enough of the clotting factor called Factor VIII, so blood does not clot properly. The antibody they built grabs Factor IX with one arm and Factor X with the other, holding them together, doing the bridging job that missing Factor VIII would normally do.
Hattori had the idea in 2000. Twenty-six years later, the drug is approved in over a hundred countries and has treated more than thirty thousand people. Somewhere in those thirty thousand are children who no longer bleed just from moving, who can take a P.E. class like their classmates. There are adults who no longer spend two afternoons a week on infusion drips. None of this shows up in your feed. But tens of thousands of daily lives look different because of the shape of that antibody. Twenty-six years is a long time to wait for the answer to matter.
The third category, the Public Service Award, went to Michael J. Fox. Fox is an actor. He was diagnosed with early-onset Parkinson's disease, a neurodegenerative condition, at 29. He went public with the diagnosis at 37. In 2000 he founded the Michael J. Fox Foundation for Parkinson's Research. To date, the foundation has funded more than three billion dollars of research toward one goal, which Fox has always stated simply, "cure Parkinson's."
Set the three stories next to each other and what surfaces is not the old line that "science takes patience." Something else.
The question you ask twenty years before its answer does not tell you what its answer will be for.
Yanagisawa wanted to know what triggered a family of orphan receptors, not how to treat narcolepsy. Fox wanted to keep acting, not to spend three decades building a foundation that would move hundreds of millions of dollars into research every year. Each of them ended up somewhere they were not aiming for, because each of them refused to stop where they started.
This is a different shape from the "find your passion first, then start" story that shows up in a lot of graduation speeches. In these three stories, the passion arrives after the honest work, not before. Yanagisawa started as a chemist, not a sleep researcher. The two small peptides his lab pulled out of rat brains are what turned him into a sleep researcher. Fox started as a sitcom actor, not an advocate. His diagnosis at 29 slowly turned him into the person that a whole disease community would eventually lean on.
So one thing to carry home:
There is a question you are curious about right now that is a little too specific, or too obscure, or too unanswered, to comfortably explain to someone else. Write it down. Write it somewhere you will still find it in twenty years. You do not have to prove that it is useful.
An honest question is a whole discipline. Its answer, years later, will show you who it was for.
### Questions to sit with
1. What is one question you are curious about right now that no one else in your life finds interesting? Write it down somewhere you will still find it in twenty years.
2. Think of one person you know whose adult life grew out of one small thing they cared about when they were young. Looking back, do you read them as lucky, or as someone who kept asking?
3. If the small thing you are doing today ends up mattering fifteen years from now because of a path it opens, where do you hope that path leads?
from Nicoletta Lanese